Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

PURPOSE: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. PATIENTS AND METHODS: A total of 153 patients with mismatch repair defic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oaknin, Ana, Pothuri, Bhavana, Gilbert, Lucy, Sabatier, Renaud, Brown, Jubilee, Ghamande, Sharad, Mathews, Cara, O'Malley, David M., Kristeleit, Rebecca, Boni, Valentina, Gravina, Adriano, Banerjee, Susana, Miller, Rowan, Pikiel, Joanna, Mirza, Mansoor R., Dewal, Ninad, Antony, Grace, Dong, Yuping, Zografos, Eleftherios, Veneris, Jennifer, Tinker, Anna V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643997/
https://www.ncbi.nlm.nih.gov/pubmed/37363992
http://dx.doi.org/10.1158/1078-0432.CCR-22-3915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643997/
https://www.ncbi.nlm.nih.gov/pubmed/37363992
http://dx.doi.org/10.1158/1078-0432.CCR-22-3915

Ejemplares similares